Immatics raises $58M in series E

Immatics Biotechnologies GmbH (Tuebingen, Germany) raised $58 million in a series E round. Existing investors dievini Hopp BioTech holding GmbH & Co. KG, Wellington Partners and AT Impf participated in the round, as did new investor Amgen Inc. (NASDAQ:AMGN).

Immatics and Amgen partnered in January to develop T cell engaging bispecific immunotherapies to treat cancer using Immatics’ XPRESIDENT target discovery platform and T cell receptor (TCR) capabilities. Amgen is responsible for clinical development, manufacturing and commercialization. XPRESIDENT identifies tumor-associated peptide candidates to act as T cell targets (see BioCentury Extra, Jan. 9)...